Dasiglucagon
Also known as: Zegalogue, ZP4207, ZP-GA-1
Dasiglucagon is a glucagon analog formulated as a stable, ready-to-use liquid for severe hypoglycemia. Its June 2026 eligibility change uses a minimum weight rather than the original age cutoff.
Quick Facts
A stable liquid rescue glucagon
Dasiglucagon, marketed as Zegalogue and developed as ZP4207/ZP-GA-1, modifies glucagon so it remains stable in aqueous solution. Traditional glucagon kits require powder/liquid mixing during an emergency; the analog can be supplied premixed as an autoinjector or prefilled syringe.
Rapid glucose release and recovery
It activates hepatic glucagon receptors to promote glycogenolysis and gluconeogenesis, releasing glucose into blood. The modifications primarily improve storage stability rather than changing the receptor’s fundamental action. In an adult type 1 diabetes Phase 3 study, median plasma-glucose recovery took 10 minutes versus 40 with placebo, with nearly all recovering by 15 minutes. A separate pediatric study supported use in children.
Supporting references: recovery.
Sources: [1]
From an age cutoff to a weight threshold
| Date | FDA action | Eligible population |
|---|---|---|
| 2021 | Severe-hypoglycemia approval in diabetes | Originally ages 6 and older |
| June 2026 | Age cutoff replaced by weight boundary | Adults and children weighing at least 20 kg, about 44 pounds |
Supporting references: Approved.
Sources: [2]
Caregiver rescue treatment
The ready-to-use medicine treats severe hypoglycemia in people with diabetes meeting the current weight requirement, often administered by a caregiver. As with glucagon, pheochromocytoma and insulinoma are contraindications.
Adverse effects and contraindication risks
Nausea/vomiting, headache, adult diarrhea and injection-site pain are common. Pheochromocytoma can lead to a pressure rise; insulinoma can lead to rebound low glucose. Serious allergy is also possible. Ready-to-use formulation does not remove these product-specific precautions.
References and further reading
This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .
- 10.2337/dc20-2995Rapid glucose release and recoveryCited in: Rapid glucose release and recovery
- accessdata.fda.govFrom an age cutoff to a weight thresholdCited in: From an age cutoff to a weight threshold
Frequently Asked Questions About Dasiglucagon
Related Peptides
Continue exploring Dasiglucagon
Search all related references →Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.